159635-47-9

Basic information

• Product Name: (R)-2-(2-tert-butoxycarbonylamino-2-methyl-propionylamino)-5-phenyl-pentanoic acid
• Synonyms: (R)-2-(2-tert-butoxycarbonylamino-2-methyl-propionylamino)-5-phenyl-pentanoic acid
• CAS NO: 159635-47-9
• Molecular Weight: 378.469
• Mol File: 159635-47-9.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: (R)-2-(2-tert-butoxycarbonylamino-2-methyl-propionylamino)-5-phenyl-pentanoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-2-(2-tert-butoxycarbonylamino-2-methyl-propionylamino)-5-phenyl-pentanoic acid(159635-47-9)
• EPA Substance Registry System: (R)-2-(2-tert-butoxycarbonylamino-2-methyl-propionylamino)-5-phenyl-pentanoic acid(159635-47-9)

Safety Data

• Hazardous Substances Data: 159635-47-9(Hazardous Substances Data)

Upstream product

• 36061-08-2 (2R)-2-amino-5-phenylpentanoic acid 
• 103290-07-9 2-tert-butoxycarbonylamino-2-methyl-propionic acid-2,5-dioxo-pyrrolidin-1-yl ester 
• 156130-68-6 2-(tert-butoxycarbonylamino)-5-phenyl-D-pentanoic acid 
• 30992-29-1 Boc-Aib-OH 

Downstream Products

• 220530-08-5 C₃₄H₄₅N₅O₇ 
• 220531-98-6 C₃₇H₄₅N₅O₆ 
• 220531-42-0 C₃₃H₄₃FN₆O₅ 
• 220530-29-0 C₃₆H₄₈N₆O₆ 
• 220535-24-0 C₃₉H₄₇N₅O₆ 
• 220530-92-7 C₃₄H₄₂F₃N₅O₆ 
• 210481-93-9 (1-Methyl-1-{(R)-4-phenyl-1-[4-(2-trifluoromethanesulfonylamino-phenyl)-piperazine-1-carbonyl]-butylcarbamoyl}-ethyl)-carbamic acid tert-butyl ester 
• 210481-94-0 (2-{4-[(R)-2-(2-tert-Butoxycarbonylamino-2-methyl-propionylamino)-5-phenyl-pentanoyl]-piperazin-1-yl}-phenylsulfamoyl)-acetic acid methyl ester 
• 210481-92-8 [1-Methyl-1-((R)-4-phenyl-1-{4-[2-(propane-2-sulfonylamino)-phenyl]-piperazine-1-carbonyl}-butylcarbamoyl)-ethyl]-carbamic acid tert-butyl ester 
• 210481-91-7 (1-{(R)-1-[4-(2-Methanesulfonylamino-phenyl)-piperazine-1-carbonyl]-4-phenyl-butylcarbamoyl}-1-methyl-ethyl)-carbamic acid tert-butyl ester 
• 174855-56-2 (1-{(R)-1-[4-(2-Amino-phenyl)-piperazine-1-carbonyl]-4-phenyl-butylcarbamoyl}-1-methyl-ethyl)-carbamic acid tert-butyl ester 
• 811795-90-1 [1-(1-{1-[1-(4-methoxy-phenyl)-1-methyl-2-oxo-2-pyrrolidin-1-yl-ethyl]-1H-imidazol-4-ylcarbamoyl}-4-phenyl-butylcarbamoyl)-1-methyl-ethyl]-carbamic acid tert-butyl ester 
• 210481-90-6 {1-Methyl-1-[(R)-4-phenyl-1-(4-o-tolyl-piperazine-1-carbonyl)-butylcarbamoyl]-ethyl}-carbamic acid tert-butyl ester 

Relevant articles and documents

Growth hormone secretagogues

What is disclosed are growth hormone secretagogues, and their uses, of the formula wherein R1 is C6H5CH2OCH2—, C6H5(CH2)3— or indol-3-ylmethyl; Y is pyrrolidin-1-yl, 4-C1-C6alkylpiperidin-1-yl or NR2R2; R2 are each independently a C1to C6alkyl; R3 is 2-napthyl or phenyl para-substituted by W; W is H, F, CF3, C1-C6alkoxy or phenyl; and R4 is H or CH3, or a pharmaceutically acceptable salt or solvate thereof.

Treatment of insulin resistance with growth hormone secretagogues

This invention is directed to methods of treating insulin resistance in a mammal which comprise administering an effective amount of a compound of formula I, where the variables are defined in the specification, or the stereoisomeric mixtures, diastereomerically enriched, diastereomerically pure, enantiomerically enriched or enantiomerically pure isomers, or the pharmaceutically acceptable salts and prodrugs thereof to said mammal. The compounds of formula I are growth hormone secretagogues and as such are useful for increasing the level of endogenous growth hormone. In another aspect this invention provides certain intermediates which are useful in the synthesis of the foregoing compounds and certain processes useful for the synthesis of said intermediates and the compounds of formula I. This invention is further directed to methods comprising administering to a human or other animal a combination of a functional somatostatin antagonist such as an alpha-2 adrenergic agonist and a compound of formula I.

Heterocyclic compounds

This invention is directed to compounds of the formula and the pharmaceutically-acceptable salts thereof, where the substituents are as defined in the Specification, which are growth hormone secretogogues and which increase the level of endogenous growth hormone. The compounds of this invention are useful for the treatment and prevention of osteoporosis, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair, attenuating protein catabolic response after a major operation, reducing cachexia and protein loss due to chronic illness, accelerating wound healing, or accelerating the recovery of burn patients or patients having undergone major surgery; improving muscle strength, mobility, maintanence of skin thickness, metabolic homeostasis or renal homeostasis. The compounds of the present invention are also useful in treating osteoporosis when used in combination with: a bisphosphonate compound such as alendronate; estrogen, premarin, and optionally progesterone; an estrogen agonist or antagonist; or calcitonin, and pharmaceutical compositions useful therefor. Further, the present invention is directed to pharmaceutical compositions useful for increasing the endogenous production or release of growth hormone in a human or other animal which comprises an effective amount of a compound of the present invention and a growth hormone secretagogue selected from GHRP-6, Hexarelin, GHRP-1, growth hormone releasing factor (GRF), IGF-1, IGF-2 or B-HT920. The invention is also directed to intermediates useful in the preparation of compounds of formula I.